Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Alzheimer's disease (AD) is a disorder without a molecular marker in peripheral tissues or a disease modifying treatment. As increasing evidence has suggested a role for glycogen synthase kinase-3 (GSK-3) in the pathogenesis of the condition we measured total GSK-3 protein (alpha and beta isoforms) and GSK-3 activity (serine 9 phosphorylation) in a group of healthy elderly people, in AD and in mild cognitive impairment (MCI). Total GSK-3 protein was increased in both AD and in MCI without a compensatory decrease in activity. These data suggest that GSK-3 assays might be a useful diagnostic marker in a readily available tissue and moreover that GSK-3 activity is increased in the prodromal phase of the disorder suggesting that inhibition of GSK-3 might be a useful therapeutic strategy.

Original publication

DOI

10.1016/j.neulet.2004.10.031

Type

Journal article

Journal

Neurosci Lett

Publication Date

03/01/2005

Volume

373

Pages

1 - 4

Keywords

Aged, Aged, 80 and over, Alzheimer Disease, Biomarkers, Cognition Disorders, Electrophoresis, Polyacrylamide Gel, Glycogen Synthase Kinase 3, Humans, Immunohistochemistry, Lymphocytes